Literature DB >> 10188913

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid.

C Fritsch1, P Lehmann, W Stahl, K W Schulte, E Blohm, K Lang, H Sies, T Ruzicka.   

Abstract

Photodynamic therapy with topically applied delta-aminolaevulinic acid is used to treat skin tumours by employing endogenously formed porphyrins as photosensitizers. This study examines the time course of porphyrin metabolite formation after topical application of delta-aminolaevulinic acid. Porphyrin biosynthesis in human skin tumours (basal cell carcinoma, squamous cell carcinoma), in psoriatic lesions, and in normal skin was investigated. Skin areas were treated with delta-aminolaevulinic acid, and levels of total porphyrins, porphyrin metabolites and proteins were measured in samples excised after 1, 2, 4, 6, 9, 12 and 24 h. There was an increase in porphyrin biosynthesis in all tissues with maximum porphyrin levels in tumours between 2 and 6 h and in psoriatic lesions 6 h after treatment. The pattern of porphyrins showed no significant difference between normal and neoplastic skin, protoporphyrin being the predominant metabolite. The results suggest that optimum irradiation time for superficial epithelial skin tumours may be as soon as 2 h after application of delta-aminolaevulinic acid, whereas for treatment of psoriatic lesions an application time of 6 h is more suitable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188913      PMCID: PMC2362712          DOI: 10.1038/sj.bjc.6690255

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  High-performance liquid chromatographic analysis of porphyrins and their isomers with radial compression columns.

Authors:  A Seubert; S Seubert
Journal:  Anal Biochem       Date:  1982-08       Impact factor: 3.365

3.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.

Authors:  J C Kennedy; R H Pottier; D C Pross
Journal:  J Photochem Photobiol B       Date:  1990-06       Impact factor: 6.252

4.  Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid.

Authors:  W E Grant; C Hopper; A J MacRobert; P M Speight; S G Bown
Journal:  Lancet       Date:  1993-07-17       Impact factor: 79.321

5.  Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?

Authors:  P Wolf; E Rieger; H Kerl
Journal:  J Am Acad Dermatol       Date:  1993-01       Impact factor: 11.527

6.  Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma.

Authors:  Q Peng; J Moan; T Warloe; J M Nesland; C Rimington
Journal:  Int J Cancer       Date:  1992-09-30       Impact factor: 7.396

7.  Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs.

Authors:  B A Goff; R Bachor; N Kollias; T Hasan
Journal:  J Photochem Photobiol B       Date:  1992-08-31       Impact factor: 6.252

8.  Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma.

Authors:  R M Szeimies; T Sassy; M Landthaler
Journal:  Photochem Photobiol       Date:  1994-01       Impact factor: 3.421

Review 9.  Photodynamic therapy in oncology: mechanisms and clinical use.

Authors:  H I Pass
Journal:  J Natl Cancer Inst       Date:  1993-03-17       Impact factor: 13.506

10.  The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells.

Authors:  J Hanania; Z Malik
Journal:  Cancer Lett       Date:  1992-08-14       Impact factor: 8.679

View more
  10 in total

1.  Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH.

Authors:  R F Lopez; M V Bentley; M B Delgado-Charro; R H Guy
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  The therapy of virus-associated epithelial tumors of the face and the lips in organ transplant recipients.

Authors:  Peter Hyckel; Peter Schleier; Astrid Meerbach; Alexander Berndt; Hartwig Kosmehl; Peter Wutzler
Journal:  Med Microbiol Immunol       Date:  2003-04-10       Impact factor: 3.402

3.  [Daylight photodynamic therapy : Back to the future?]

Authors:  P Lehmann
Journal:  Hautarzt       Date:  2018-02       Impact factor: 0.751

4.  Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.

Authors:  Stephen Chad Kanick; Scott C Davis; Yan Zhao; Tayyaba Hasan; Edward V Maytin; Brian W Pogue; M Shane Chapman
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

5.  Noninvasive Optical Imaging of UV-Induced Squamous Cell Carcinoma in Murine Skin: Studies of Early Tumor Development and Vitamin D Enhancement of Protoporphyrin IX Production.

Authors:  Kishore R Rollakanti; Sanjay Anand; Scott C Davis; Brian W Pogue; Edward V Maytin
Journal:  Photochem Photobiol       Date:  2015-09-25       Impact factor: 3.421

Review 6.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  [Photodynamic therapy: non-oncologic indications].

Authors:  S Karrer; R-M Szeimies
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

Review 8.  Anti-microbial photodynamic therapy: useful in the future?

Authors:  Tim Maisch
Journal:  Lasers Med Sci       Date:  2006-11-21       Impact factor: 2.555

9.  Comparative Study of Photodynamic Therapy with Topical Methyl Aminolevulinate versus 5-Aminolevulinic Acid for Facial Actinic Keratosis with Long-Term Follow-Up.

Authors:  Dong-Yeob Ko; Ki-Ho Kim; Ki-Hoon Song
Journal:  Ann Dermatol       Date:  2014-06-12       Impact factor: 1.444

10.  A Formulation Study of 5-Aminolevulinic Encapsulated in DPPC Liposomes in Melanoma Treatment.

Authors:  Ming-Wei Lin; Yaw-Bin Huang; Chun-Lin Chen; Pao-Chu Wu; Chien-Ying Chou; Ping-Ching Wu; Shih-Ya Hung
Journal:  Int J Med Sci       Date:  2016-06-18       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.